1beta,3beta-二羟基-18-去甲雄甾-5-烯并[6,5,4-Bc]呋喃-8,11,13-三烯-7,17-二酮 | 56617-66-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 中文名称: 1beta,3beta-二羟基-18-去甲雄甾-5-烯并[6,5,4-Bc]呋喃-8,11,13-三烯-7,17-二酮
• 英文名称: Demethoxyviridiol
• 英文别名: (1R,16S,18R)-16,18-dihydroxy-1-methyl-13-oxapentacyclo[10.6.1.02,10.05,9.015,19]nonadeca-2(10),3,5(9),12(19),14-pentaene-6,11-dione
• CAS: 56617-66-4
• 化学式: C₁₉H₁₆O₅
• 分子量: 324.3
• InChiKey: OSSCBUARECIOCW-KSMMKXTCSA-N

物化性质

• 溶解度：
  DMSO溶解度：0.0(最大浓度 mg/mL);0.0(最大浓度 mM)
• LogP：
  0.537 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA
  申请人：Marks Andrew R.

  公开号：US20090274739A1

  公开（公告）日：2009-11-05

  The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising delivery of such compositions or intraluminal devices to subjects in need thereof. The compositions, intraluminal devices, and methods of the invention are particularly well-suited for the treatment or prevention of vascular stenosis and restenosis in obese and diabetic subjects.
• Ligand-Directed Covalent Modification of Protein
  申请人：Celgene CAR LLC

  公开号：US20170218353A1

  公开（公告）日：2017-08-03

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
• [EN] LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN<br/>[FR] MODIFICATION COVALENTE DE PROTÉINE, DIRIGÉE SUR UN LIGAND
  申请人：AVILA THERAPEUTICS INC

  公开号：WO2011082285A1

  公开（公告）日：2011-07-07

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.